Growth of $10K Avg Annual Total Return %   10 YR 5 YR 1 YR YTD Market Return 17.16% 14.59% 37.27% 12.23% Lipper Pct. Rank 10 29 78 62 NAV Return 15.65% 13.72% 20.60% 4.20% Lipper Pct. Rank 13 31 87 87 Premium/Discount History Premium/Discount 10 YR Avg 5 YR Avg YTD Avg -4.661% -6.248% -6.290%

NAV $21.24 Market Price $20.85 Net Change -$0.38 Market Change -$0.09 Premium/Discount -1.84% 1 YR NAV Return 20.595% 1 YR NAV Rank 87 12-Mo Yield as of 4/30/2021 Yield Def Income Only Yield 0.00% Distribution Yield (Market) 12.44% Most Recent Income Dividend $0.410 Ex-Div Date 5/27/2021 Most Recent Cap Gain Dividend $0.410 Ex-Div Date 5/27/2021 Dividend Frequency Annually YTD Dividends -- YTD Capital Gains $0.430 Inception Date 5/8/1992 Fund Advisor Tekla Capital Management LLC Manager & Tenure Team Managed Phone 800-451-2597 Website www.teklacap.com Total Net Assets (mil) as of 5/31/2021 $493.0 % Leveraged Assets as of 9/30/2020 -- Portfolio Turnover 51.00% Mgmt Fees 0.993% Expense Ratio 1.220% Fund Objective The Fund seeks long-term capital appreciation by investing primarily in equity and related securities of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in health care, agriculture and environmental management.

Top Holdings (as of 12/31/2020) Illumina Inc ORD 5.11% Amgen Inc ORD 5.09% Gilead Sciences Inc ORD 4.75% Regeneron Pharmaceuticals Inc ORD 4.67% Vertex Pharmaceuticals Inc ORD 4.41% Alexion Pharmaceuticals Inc ORD 4.15% Seagen Inc ORD 3.51% Biogen Inc ORD 3.17% Sarepta Therapeutics Inc ORD 2.12% Moderna Inc ORD 1.99%

Top Sectors (as of 12/31/2020) Health Care 89.55% Non Classified Equity 7.54%

The views and opinions expressed in the replay are for informational and educational purposes only as of the date of production/writing and may change without notice at any time based on factors such as market conditions or legal and regulatory developments. This material may contain “forward-looking” information that is not purely historical in nature. Such information may include, among other things, projections, forecasts, estimates of market returns, and proposed or expected portfolio composition. Past performance is no guarantee of future results. Investing involves risk; principal loss is possible. This material is not intended to be a recommendation or investment advice, does not constitute a solicitation to buy, sell or hold a security or an investment strategy, and is not provided in a fiduciary capacity. Shares of closed-end funds are subject to investment risks, including the possible loss of principal invested. Closed-end funds frequently trade at a discount to their net asset value (NAV).